Sight Sciences Inc (OQ:SGHT)

Business Focus: Medical Equipment, Supplies & Distribution

Get the company report for the most recent outlook updated daily

May 07, 2024 04:05 pm ET

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will...

May 02, 2024 04:05 pm ET

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial...

Apr 29, 2024 08:05 am ET

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive...

Apr 18, 2024 04:05 pm ET

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 10, 2024 04:05 pm ET

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today...

Apr 02, 2024 04:05 pm ET

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annua

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of...

Mar 26, 2024 04:05 pm ET

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...

Mar 07, 2024 04:05 pm ET

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...

Feb 22, 2024 04:05 pm ET

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...

Feb 14, 2024 04:05 pm ET

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...

Jan 23, 2024 04:05 pm ET

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the closing of an up to...

Jan 08, 2024 04:05 pm ET

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported...

Dec 28, 2023 09:15 am ET

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Dec 18, 2023 04:05 pm ET

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the...

Dec 08, 2023 08:05 am ET

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OM

Nov 11, 2023 08:28 am ET

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sight Sciences, Inc. (NASDAQ: SGHT) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Sight Sciences, Inc. (NASDAQ: SGHT) (“Sight Sciences”) on behalf of the company’s investors. Since January 2023, shares of Sight Sciences’ common stock have declined in value from a trading price...

Nov 07, 2023 04:05 pm ET

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Nov 02, 2023 12:54 am ET

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Sight Sciences, Inc.; Urges Sight Sciences Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Abbott Cooper PLLC is investigating Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Sight Sciences’ board of directors (the “Board”) has...

Oct 24, 2023 04:05 pm ET

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 19, 2023 04:05 pm ET

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

Oct 12, 2023 04:05 pm ET

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the Amer

Oct 03, 2023 08:30 am ET

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medication

Sep 12, 2023 12:05 pm ET

Investigation of Sight Sciences, Inc. (SGHT) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether Sight Sciences, Inc. (“Sight Sciences” or “the Company”) (NASDAQ: SGHT) complied with federal securities laws. On September 11, 2023, Sight Sciences announced its third quarter 2023 revenue guidance and...

Sep 11, 2023 04:06 pm ET

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

Sep 11, 2023 04:05 pm ET

Sight Sciences Appoints Matt Link as Chief Commercial Officer

Aug 30, 2023 04:05 pm ET

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

Aug 03, 2023 04:05 pm ET

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

Jul 20, 2023 04:05 pm ET

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the...

Jul 20, 2023 08:30 am ET

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Techno

Jun 21, 2023 08:30 am ET

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

Jun 09, 2023 04:05 pm ET

Sight Sciences Announces Addition of New Director Catherine Mazzacco

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces that Catherine Mazzacco was...

May 23, 2023 08:30 am ET

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the publication of two-year results of the ROMEO (Retrospective,...

May 06, 2023 11:30 am ET

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Regis

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables procedures intended to improve patients' lives, today announced the results from a 12-month...

May 04, 2023 04:05 pm ET

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the first...

May 01, 2023 04:05 pm ET

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, announced today that two of its proprietary glaucoma and dry eye technologies, the...

Apr 26, 2023 04:05 pm ET

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Bank of America Securities 2023...

Apr 20, 2023 04:05 pm ET

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March...

Apr 13, 2023 04:05 pm ET

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

Apr 03, 2023 04:05 pm ET

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

Mar 30, 2023 08:00 am ET

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

Mar 13, 2023 04:05 pm ET

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 09, 2023 08:30 am ET

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that provides solutions intended to transform care and improve patients' lives, today announced the United States...

Feb 23, 2023 04:05 pm ET

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the fourth quarter and full...

Feb 22, 2023 04:05 pm ET

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Jan 26, 2023 08:30 am ET

Sight Sciences Announces 1,000th TearCare® Customer Installation

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its...

Jan 09, 2023 04:20 pm ET

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

Jan 04, 2023 09:00 am ET

Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry

Glaucoma Qdata Contains More than 341,000 MIGS Records with Nearly Three Years of Patient Follow-Up

Dec 08, 2022 08:30 am ET

Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, is pleased to report independent data addressing a frequent question from eyecare...

Nov 22, 2022 08:30 am ET

Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler 34th Annual...

Nov 10, 2022 04:05 pm ET

Sight Sciences Reports Third Quarter 2022 Financial Results

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2022....

Nov 03, 2022 08:30 am ET

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previ

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced International Ophthalmology has published clinical...

Oct 20, 2022 05:20 pm ET

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended...

Sep 29, 2022 08:30 am ET

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives today announced Clinical Ophthalmology has published data from a subgroup analysis of...

Sep 28, 2022 08:30 am ET

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology

Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO...

Sep 16, 2022 08:00 am ET

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, Italy on Friday, September...

Sep 13, 2022 03:01 am ET

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the completion of enrollment in the SAHARA Trial, a first of its...

Sep 02, 2022 08:00 am ET

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare...

Aug 25, 2022 04:05 pm ET

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Inaugural...

Aug 23, 2022 08:03 am ET

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

Aug 16, 2022 08:01 am ET

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced 36-month post-surgery follow-up results of the...

Aug 11, 2022 04:05 pm ET

Sight Sciences Reports Second Quarter 2022 Financial Results

Jul 28, 2022 08:00 am ET

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June...

Jul 19, 2022 04:26 pm ET

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors,...

May 31, 2022 08:00 am ET

Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced publication in Clinical Ophthalmology of its...

May 19, 2022 08:00 am ET

Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium

May 10, 2022 04:05 pm ET

Sight Sciences Reports First Quarter 2022 Financial Results

Apr 29, 2022 08:00 am ET

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Apr 20, 2022 04:05 pm ET

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI® Surgical System will be...

Apr 14, 2022 04:05 pm ET

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quarter ended March 31,...

Mar 24, 2022 04:05 pm ET

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended...

Mar 24, 2022 04:04 pm ET

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT...

Mar 16, 2022 08:00 am ET

Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Brenda Becker to its Board of Directors,...

Mar 03, 2022 04:05 pm ET

Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quarter and year ended...

Mar 02, 2022 08:00 am ET

Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI® Surgical System will be...

Feb 21, 2022 04:05 pm ET

Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Citi Virtual...

Feb 17, 2022 08:00 am ET

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for Too Late” educational...

Jan 10, 2022 05:50 am ET

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced preliminary unaudited financial results for the fourth...

Dec 22, 2021 08:00 am ET

Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k)...

Nov 18, 2021 04:05 pm ET

Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler...

Nov 17, 2021 08:00 am ET

Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data...

Nov 10, 2021 04:05 pm ET

Sight Sciences Reports Third Quarter 2021 Financial Results

Nov 10, 2021 04:04 pm ET

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults wi

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced that the Food and Drug Administration (FDA) has granted...

Oct 27, 2021 04:05 pm ET

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a...

Oct 20, 2021 08:00 am ET

Sight Sciences Announces TearCare® Clinical Data Published in Cornea

Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced publication in the journal Cornea of positive results from OLYMPIA, a...

Sep 16, 2021 06:29 pm ET

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents...

Aug 26, 2021 04:05 pm ET

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate...

Aug 24, 2021 08:00 am ET

Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-A

Aug 12, 2021 04:05 pm ET

Sight Sciences Reports Second Quarter 2021 Financial Results

Aug 02, 2021 04:34 pm ET

Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results during a conference call...

Jul 22, 2021 08:13 pm ET

Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced that data from multiple retrospective and prospective clinical...

Jul 19, 2021 05:22 pm ET

Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases, today announced the closing of its...

Jul 14, 2021 06:53 pm ET

Sight Sciences Announces Pricing of Initial Public Offering

Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, today announced the pricing of its...

Ad blocking detected

Sight Sciences Inc (OQ:SGHT)

Business Focus: Medical Equipment, Supplies & Distribution